Detalhe da pesquisa
1.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.
Oncologist
; 28(8): 714-721, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36952233
2.
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Invest New Drugs
; 40(2): 290-299, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562230
3.
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a singlecenter, multiarm phase Ib study.
Invest New Drugs
; 40(2): 463, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34731355
4.
Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience.
J Hematol
; 11(3): 113-120, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35837373
5.
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study.
J Immunother Precis Oncol
; 5(1): 10-12, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35663832